Business Context and Reporting Period
Company: Geron Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 1999
Business Overview: Geron is a biopharmaceutical company focused on discovering and developing therapeutic and diagnostic products for cancer and age-related degenerative diseases. Key technology platforms include telomerase inhibitors, stem cell therapies, and nuclear transfer technology.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sep 30, 1999 | Nine Months Ended Sep 30, 1999 | Nine Months Ended Sep 30, 1998 |
|---|---|---|---|
| Total Revenues | $1,276 | $4,117 | $5,288 |
| Net Loss | $(6,940) | $(38,283) | $(7,053) |
| Net Loss Per Share (Basic/Diluted) | $(0.42) | $(2.55) | $(0.63) |
| Cash and Cash Equivalents (Sep 30, 1999) | $27,794 | ||
| Total Investments (Short & Long Term) | $18,663 | ||
| Convertible Debentures Outstanding | $19,851 | ||
| Accumulated Deficit | $(94,910) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenues for the nine months ended September 30, 1999, decreased to $4.1 million from $5.3 million in the prior year. This was primarily due to the expiration of the Kyowa Hakko collaborative agreement in April 1998, leaving only the Pharmacia & Upjohn agreement as a revenue source.
- Significant Increase in Net Loss: Net loss for the nine months ended September 30, 1999, widened significantly to $38.3 million compared to $7.1 million in 1998. The primary driver was a one-time charge of $23.4 million for acquired research technology related to the acquisition of Roslin Bio-Med Ltd.
- Operating Expenses: Research and development expenses increased to $16.0 million (nine months 1999) from $11.3 million (nine months 1998) due to increased scientific headcount. General and administrative expenses also rose due to the integration of Roslin Bio-Med operations in Scotland.
- Liquidity Position: Cash and cash equivalents increased to $27.8 million from $16.4 million at year-end 1998, bolstered by the sale of Series B and Series C convertible debentures and cash acquired from Roslin Bio-Med.
Guidance, Outlook, Risks, and Unusual Items
Management Commentary and Outlook
Management estimates that existing capital resources, combined with payments from the Pharmacia & Upjohn agreement and interest income, will fund operations through the second quarter of 2001. The company expects to incur additional operating losses as R&D efforts expand. Future profitability depends on successful product development, regulatory approvals, and commercialization.
Unusual Items and Contingencies
- Roslin Bio-Med Acquisition: The company acquired Roslin Bio-Med Ltd. in May 1999. The purchase price allocation resulted in a $23.4 million charge to acquired research expense and the capitalization of $17.2 million in intangible assets (research agreement with Roslin Institute).
- Series C Debenture Default Risk: On September 30, 1999, the company sold $12.5 million in Series C convertible debentures. The company currently lacks sufficient authorized shares to allow full conversion. It must obtain stockholder approval to increase authorized shares by March 31, 2000. Failure to do so constitutes a default, obligating the company to redeem the debentures at 115% of principal (approx. $14.4 million).
- Research Funding Commitments: The company has committed approximately $20.5 million in research funding to the Roslin Institute over six years.
Risk Factors
- Product Development: All product programs are in early stages; there is no assurance of commercially viable products.
- Capital Needs: The company has a history of operating losses and will require substantial additional capital to fund future operations.
- Regulatory and Ethical Risks: Stem cell and nuclear transfer research face significant ethical, legal, and regulatory scrutiny, including potential government restrictions.
- Intellectual Property: Success depends on obtaining and enforcing patents, which is uncertain in the biotechnology sector.
Investor Verification Checklist
- Stockholder Approval Deadline: Verify if the company secures stockholder approval to increase authorized shares by March 31, 2000, to avoid a $14.4 million redemption obligation on Series C debentures.
- Collaborative Revenue Sustainability: Monitor the status of the Pharmacia & Upjohn agreement, which expires in January 2000, as it is the primary revenue source.
- Roslin Integration: Assess the progress and cost of integrating Roslin Bio-Med operations and the status of the $20.5 million funding commitment to the Roslin Institute.
- Cash Burn Rate: Track the rate of cash consumption against the projected runway to the second quarter of 2001.
- Regulatory Environment: Watch for changes in government funding or regulations regarding human pluripotent stem cell and nuclear transfer research.